Postoperative outcome between TIVA and inhalation groups.

<p>Postoperative outcome between TIVA and inhalation groups.</p

Flow chart of the retrospective study.

<p>One hundred and eighty patients were enrolled from medical records using key words “free flap reconstruction”. Four patients were excluded because they also had hypopharynx cancer that needed not only free flap reconstruction but also jejunum tissue transfer. Seven patients were excluded because they either had end-organ disease or a psychiatric disorder that may have complicated their recovery course. Finally, fourteen patients were excluded due to incomplete medical records. A total 156 of patients were included in the final analysis.</p

Comparison between the TIVA and inhalation groups.

<p>Comparison between the TIVA and inhalation groups.</p

Incidence of acute coronary syndrome by prescriptions.

<p>Incidence of acute coronary syndrome by prescriptions.</p

Patient flow diagram.

<p>Patient flow diagram.</p

Subgroup analyses.

<p><b>A</b>. Hazard ratios of myocardial infarction (MI) in specific subgroups of sulfonylureas treated patients by using insulin as reference group. <b>B</b>. Hazard ratios of MI in specific subgroups of meglitinides treated patients by using insulin as reference group. <b>C</b>. Hazard ratios of MI in specific subgroups of TZD treated patients by using insulin as reference group. Abbreviations: CI, confidence interval; CVD, cardiovascular disease (combination of coronary artery disease, ischemic stroke, hemorrhagic stroke, peripheral artery disease); CHF, congestive heart failure; HTN, hypertension; HR, hazard ratio; TZD, thiazolidinedione.</p

Demographic and clinical characteristics of study subjects.

<p>Demographic and clinical characteristics of study subjects.</p

Adjusted hazard ratios (95% CI) of developing myocardial infarction in patients receiving sulfonylurea, meglitinides or TZD with insulin treatment as the reference and subgroup analyses.

<p>Adjusted hazard ratios (95% CI) of developing myocardial infarction in patients receiving sulfonylurea, meglitinides or TZD with insulin treatment as the reference and subgroup analyses.</p

Kaplan–Meier curves showing the development of myocardial infarction (MI) among patients with Insulin (black), sulfonylureas (red), meglitinides (green) and TZD (blue).

<p>The log-rank analysis showed significant different (P < 0.001). Abbreviation: TZD, thiazolidinedione.</p